Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02000947
Registration number
NCT02000947
Ethics application status
Date submitted
27/11/2013
Date registered
4/12/2013
Date last updated
31/10/2019
Titles & IDs
Public title
A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
Query!
Scientific title
A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
Query!
Secondary ID [1]
0
0
2015-003715-38
Query!
Secondary ID [2]
0
0
D4190C00006
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
D4190C00006
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
NSCLC
0
0
Query!
Non-small Cell Lung Cancer
0
0
Query!
Lung Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - MEDI4736
Treatment: Drugs - Tremelimumab
Treatment: Drugs - tremelimumab
Experimental: Dose Escalation - MEDI4736 and tremelimumab received by intravenous infusion.
Experimental: Arm A - Medi4736 and tremelimumab received by intravenous infusion
Experimental: Arm B - MEDI4736 and tremelimumab received by intravenous infusion
Experimental: Arm C - MEDI4736 and tremelimumab received by intravenous infursion
Treatment: Drugs: MEDI4736
MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).
Treatment: Drugs: Tremelimumab
Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
Treatment: Drugs: tremelimumab
Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of subjects reporting adverse events
Query!
Assessment method [1]
0
0
The number of subjects reporting adverse events (AEs) and number (percentage) of subjects reporting serious adverse events (SAEs) as graded by CTCAE Version 4.03
Query!
Timepoint [1]
0
0
Screening through 90 days after the last dose of study medication
Query!
Primary outcome [2]
0
0
Objective response
Query!
Assessment method [2]
0
0
Best overall response of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as defined as the best response among all overall responses recorded from the start of treatment until progression, or the last evaluable disease assessment in the absence of progressive disease (PD) prior to the initiation of subsequent anti-cancer therapy, or discontinuation from the study, whichever occurs first.
Query!
Timepoint [2]
0
0
At least 24 weeks as compared to baseline
Query!
Primary outcome [3]
0
0
Number of subjects experiencing dose-limiting toxicities (DLTs)
Query!
Assessment method [3]
0
0
The maximum tolerated dose (MTD), which is the highest dose within a cohort where no more than 1 out of 6 subjects experience DLTs or the highest protocol-defined dose for each agent in the absence of exceeding the MTD, will be evaluated using the following safety assessments: adverse events, serious advents, laboratory evaluations, vital signs, physical examinations, and electrocardiogram (ECG) results. Measurements will be aggregated to determine whether a subject has experienced a DLT as assessed by the investigator.
Query!
Timepoint [3]
0
0
Depending upon the cohort, the DLT evaluation period is from the 1st dose of study medication until (1) the 3rd dose of MEDI4736 and tremelimumab (2) the 2nd dose of MEDI4736 and tremelimumab or (3) the 3rd dose of MEDI4736 and 2nd dose of tremelimumab
Query!
Secondary outcome [1]
0
0
Immunogenicity of tremelimumab in combination with MEDI4736
Query!
Assessment method [1]
0
0
Immunogenicity of MEDI4736 and tremelimumab will include the number and percentage of subjects who develop detectable anti-drug antibodies (ADAs).
Query!
Timepoint [1]
0
0
During treatment through study completion, about 2 years
Query!
Secondary outcome [2]
0
0
Antitumor activity of tremelimumab in combination with MEDI4736
Query!
Assessment method [2]
0
0
Antitumor activity will include objective response (OR) and disease control (DC) based on RECIST Version 1.1, duration of response (DoR), progression-free survival (PFS), and overall survival (OS).
Query!
Timepoint [2]
0
0
During treatment through study completion, about 2 years
Query!
Secondary outcome [3]
0
0
Pharmacokinetic parameters
Query!
Assessment method [3]
0
0
Assessment of PK of MEDI4736 and tremelimumab will include individual MEDI4736 and tremelimumab concentrations in serum, and PK parameters including peak concentration (Cmax), area under the concentration-time curve (AUC), clearance (CL), and half-life (t½).
Query!
Timepoint [3]
0
0
During treatment through study completion, about 2 years
Query!
Secondary outcome [4]
0
0
Number of subjects reporting adverse events
Query!
Assessment method [4]
0
0
The number of subjects reporting adverse events (AEs) and number (percentage) of subjects reporting serious adverse events (SAEs) as graded by CTCAE Version 4.03
Query!
Timepoint [4]
0
0
Screening through 90 days after the last dose of study medication
Query!
Eligibility
Key inclusion criteria
1. Age = 18 years
2. Advanced non-small cell lung cancer
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
4. Adequate organ and marrow function
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
101
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer
treatment
2. Current or prior use of immunosuppressive medication within 14 days before the first
dose of study drugs
3. Active or prior documented autoimmune disease within the last 2 years.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
25/10/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
17/09/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
459
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Darlinghurst
Query!
Recruitment hospital [2]
0
0
Research Site - Gosford
Query!
Recruitment hospital [3]
0
0
Research Site - Kogarah
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
2250 - Gosford
Query!
Recruitment postcode(s) [3]
0
0
2217 - Kogarah
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Delaware
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Massachusetts
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New Hampshire
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New York
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
North Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Ohio
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Oregon
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Texas
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Virginia
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Washington
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
West Virginia
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Bruxelles
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Gent
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Liege
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Bordeaux Cedex
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Dijon
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
La Tronche
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Lille
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Lyon
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Marseille
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Montpellier Cedex 5
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Saint Herblain
Query!
Country [33]
0
0
Italy
Query!
State/province [33]
0
0
Bologna
Query!
Country [34]
0
0
Italy
Query!
State/province [34]
0
0
Milano
Query!
Country [35]
0
0
Italy
Query!
State/province [35]
0
0
Rozzano
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Saronno
Query!
Country [37]
0
0
Italy
Query!
State/province [37]
0
0
Siena
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Sondrio
Query!
Country [39]
0
0
Korea, Republic of
Query!
State/province [39]
0
0
Cheongju-si
Query!
Country [40]
0
0
Korea, Republic of
Query!
State/province [40]
0
0
Incheon
Query!
Country [41]
0
0
Korea, Republic of
Query!
State/province [41]
0
0
Seongnam-si
Query!
Country [42]
0
0
Korea, Republic of
Query!
State/province [42]
0
0
Seoul
Query!
Country [43]
0
0
Spain
Query!
State/province [43]
0
0
Barcelona
Query!
Country [44]
0
0
Spain
Query!
State/province [44]
0
0
Jaen
Query!
Country [45]
0
0
Spain
Query!
State/province [45]
0
0
Madrid
Query!
Country [46]
0
0
Spain
Query!
State/province [46]
0
0
Malaga
Query!
Country [47]
0
0
Spain
Query!
State/province [47]
0
0
Sevilla
Query!
Country [48]
0
0
Spain
Query!
State/province [48]
0
0
Valencia
Query!
Country [49]
0
0
Taiwan
Query!
State/province [49]
0
0
Tainan
Query!
Country [50]
0
0
Taiwan
Query!
State/province [50]
0
0
Taipei
Query!
Country [51]
0
0
United Kingdom
Query!
State/province [51]
0
0
London
Query!
Country [52]
0
0
United Kingdom
Query!
State/province [52]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
MedImmune LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to determine if MEDI4736 will be adequately tolerated in
combination with tremelimumab in subjects with advanced non-small cell lung cancer (NSCLC).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02000947
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
MedImmune LLC
Query!
Address
0
0
MedImmune LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02000947
Download to PDF